[go: up one dir, main page]

PE20151335A1 - Composicion farmaceutica con biodisponibilidad mejorada - Google Patents

Composicion farmaceutica con biodisponibilidad mejorada

Info

Publication number
PE20151335A1
PE20151335A1 PE2015001370A PE2015001370A PE20151335A1 PE 20151335 A1 PE20151335 A1 PE 20151335A1 PE 2015001370 A PE2015001370 A PE 2015001370A PE 2015001370 A PE2015001370 A PE 2015001370A PE 20151335 A1 PE20151335 A1 PE 20151335A1
Authority
PE
Peru
Prior art keywords
biodavailability
improved
pharmaceutical composition
fluorophenyl
chloro
Prior art date
Application number
PE2015001370A
Other languages
English (en)
Inventor
Steve Lomuscio
Hua Ma
Michael Allen Matchett
Harpreet K Sandhu
Navnit Hargovindas Shah
yu-e Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50023547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151335(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20151335A1 publication Critical patent/PE20151335A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Referida a una dispersion solida que comprende al acido 4-{[(2R,3S,4R,5S)-4-(4-cloro-2-fluorofenil)-3-(3-cloro-2-fluorofenil)-4-ciano-5-(2,2-dimetilpropil)-pirrolidin-2-carbonil]-amino}-3-metoxibenzoico de formula (A) y un polimero estabilizador tal como el acetato-succinato de hipromelosa (HPMCAS), donde la proporcion entre la cantidad del compuesto A y el polimero se encuentra entre 5:95 y 70:30. Tambien esta referida a un metodo de preparacion
PE2015001370A 2013-01-22 2014-01-20 Composicion farmaceutica con biodisponibilidad mejorada PE20151335A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361755074P 2013-01-22 2013-01-22

Publications (1)

Publication Number Publication Date
PE20151335A1 true PE20151335A1 (es) 2015-09-18

Family

ID=50023547

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001370A PE20151335A1 (es) 2013-01-22 2014-01-20 Composicion farmaceutica con biodisponibilidad mejorada

Country Status (26)

Country Link
US (2) US9427427B2 (es)
EP (1) EP2948141B1 (es)
JP (1) JP6192244B2 (es)
KR (1) KR101737250B1 (es)
CN (3) CN104936589A (es)
AR (1) AR094548A1 (es)
AU (1) AU2014210103B2 (es)
BR (1) BR112015015758B1 (es)
CA (1) CA2892025C (es)
CL (1) CL2015001649A1 (es)
CR (1) CR20150287A (es)
EA (1) EA028009B1 (es)
ES (1) ES3035191T3 (es)
HK (1) HK1211217A1 (es)
IL (1) IL239657B (es)
MA (1) MA38289A1 (es)
MX (1) MX372668B (es)
MY (1) MY192032A (es)
NZ (1) NZ708272A (es)
PE (1) PE20151335A1 (es)
PH (1) PH12015501620B1 (es)
PL (1) PL2948141T3 (es)
SG (1) SG11201504499VA (es)
UA (1) UA116004C2 (es)
WO (1) WO2014114575A1 (es)
ZA (1) ZA201504187B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA39877A (fr) * 2014-04-15 2017-02-22 Hoffmann La Roche Formes solides d'un composé pharmaceutiquement actif
PT107846B (pt) * 2014-08-01 2019-03-22 Hovione Farm S A Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
KR102387089B1 (ko) 2014-12-05 2022-04-14 아라곤 파마슈티컬스, 인코포레이티드 항암 조성물
PL3226842T3 (pl) * 2014-12-05 2021-07-12 Aragon Pharmaceuticals, Inc. Kompozycje przeciwnowotworowe
KR102348320B1 (ko) 2014-12-05 2022-01-10 아라곤 파마슈티컬스, 인코포레이티드 항암 조성물
US12133911B2 (en) 2015-06-09 2024-11-05 Capsugel Belgium Nv Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
GB201609222D0 (en) 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
CN109152745A (zh) * 2017-04-21 2019-01-04 株式会社生物研究 利用脂质作为研磨工序中的润滑剂的制备活性物质纳米粒子的方法
MY199479A (en) * 2017-07-04 2023-11-01 Jiangsu Hengrui Medicine Co Pharmaceutical composition and method for preparing same
WO2019094688A1 (en) * 2017-11-10 2019-05-16 Dispersol Technologies, Llc Improved drug formulations
ES2967689T3 (es) 2018-04-06 2024-05-03 Capsugel Belgium Nv Proceso de secado por aspersión para partículas de baja relación de aspecto que comprenden poli[(metacrilato de metilo)-co-(ácido metacrílico)]
WO2019213106A1 (en) 2018-04-30 2019-11-07 Teva Pharmaceuticals International Gmbh Solid state forms of idasanutlin
TWI849043B (zh) * 2019-01-25 2024-07-21 英屬開曼群島商百濟神州有限公司 B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途
PE20212270A1 (es) * 2019-03-11 2021-11-30 Ptc Therapeutics Inc Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
TW202100527A (zh) * 2019-05-31 2021-01-01 大陸商江蘇恆瑞醫藥股份有限公司 一種固體分散體及其製備方法
WO2021056048A1 (en) * 2019-09-23 2021-04-01 Bionomics Limited Therapeutic formulations and uses thereof
JP7731883B2 (ja) * 2019-12-02 2025-09-01 アストラゼネカ・アクチエボラーグ ６－（２－クロロ－６－メチルピリジン－４－イル）－５－（４－フルオロフェニル）－１，２，４－トリアジン－３－アミンの固形製剤処方物
WO2021123088A1 (en) * 2019-12-20 2021-06-24 Intervet International B.V. A pharmaceutical composition of a pyrazole compound dispersed in a polymer matrix
TW202521099A (zh) * 2020-06-05 2025-06-01 美商應用材料股份有限公司 經塗佈的藥物組成物及製備彼之方法
AU2021341936A1 (en) * 2020-09-09 2023-05-25 Crinetics Pharmaceuticals, Inc. Formulations of a somatostatin modulator
CN112022812B (zh) * 2020-11-03 2021-01-29 上海亚盛医药科技有限公司 一种包含杂环类化合物的组合物、其制备方法和应用
AU2021391823A1 (en) 2020-12-03 2023-06-29 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
CA3216359A1 (en) 2021-04-07 2022-10-13 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
EP4119128A1 (en) * 2021-07-13 2023-01-18 Dr. Falk Pharma Gmbh Pharmaceutical composition for the oral administration of poorly soluble drugs comprising an amorphous solid dispersion
KR20250043410A (ko) * 2022-07-26 2025-03-28 파마 싱크, 엘엘씨 유리딘삼인산 비정질 제형 및 이의 용도
CN116251064A (zh) * 2022-11-15 2023-06-13 温州医科大学 一种以聚赖氨酸或聚谷氨酸为载体的甲苯咪唑无定形组合物
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
GB9511220D0 (en) * 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
CZ293841B6 (cs) 1996-05-20 2004-08-18 Janssenápharmaceuticaán@Áv Částice s obsahem itrakonazolu
SE9700655L (sv) 1997-02-25 1998-05-11 Neste Oy Förfarande för framställning av ftalsyraanhydrid
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
IL143580A0 (en) 1998-12-11 2002-04-21 Pharmasolutions Inc Pharmaceutical compositions containing lipophilic drugs and methods for the preparation thereof
ATE400251T1 (de) 1999-02-09 2008-07-15 Pfizer Prod Inc Zusammensetzungen basischer arzneistoffe mit verbesserter bioverfügbarkeit
US6057289A (en) 1999-04-30 2000-05-02 Pharmasolutions, Inc. Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system
MXPA03000520A (es) 2000-07-17 2003-10-06 Yamanouchi Pharma Co Ltd Composicion farmaceutica mejorada en absorbabilidad peroral..
HRP20030339A2 (en) 2000-10-31 2005-04-30 Boehringer Ingelheim Pharmaceuticals Inc. Oral dosage self-emulsifying formulations of pyranone protease inhibitors
KR20060021278A (ko) 2002-08-15 2006-03-07 윤킹 리우 고체 나노미터 의약 및 이의 제조방법
US7438261B2 (en) 2004-09-09 2008-10-21 David R. Porter Stratospheric balloon utilizing electrostatic inflation of walls
EP2001497A4 (en) 2006-03-20 2012-11-07 Vertex Pharma PHARMACEUTICAL COMPOSITIONS
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
AU2010232670B2 (en) * 2009-04-03 2015-07-09 F. Hoffmann-La Roche Ag Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
CN102871950B (zh) * 2011-07-15 2016-04-20 上海睿智化学研究有限公司 一种熊果酸固体分散体及其制备方法
US20130245089A1 (en) * 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Method for administration
US20140128431A1 (en) * 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability

Also Published As

Publication number Publication date
EP2948141A1 (en) 2015-12-02
MX372668B (es) 2020-04-23
HK1211217A1 (en) 2016-05-20
MA38289A1 (fr) 2017-01-31
ES3035191T3 (en) 2025-08-29
WO2014114575A1 (en) 2014-07-31
KR20150097792A (ko) 2015-08-26
EP2948141B1 (en) 2025-05-14
CA2892025C (en) 2022-02-15
AU2014210103B2 (en) 2018-09-06
US20140206742A1 (en) 2014-07-24
UA116004C2 (uk) 2018-01-25
EA028009B1 (ru) 2017-09-29
AR094548A1 (es) 2015-08-12
CN112370427A (zh) 2021-02-19
CN112353762A (zh) 2021-02-12
KR101737250B1 (ko) 2017-05-17
CN104936589A (zh) 2015-09-23
BR112015015758A2 (pt) 2018-06-19
MX2015008911A (es) 2015-10-22
SG11201504499VA (en) 2015-08-28
CL2015001649A1 (es) 2015-10-23
JP6192244B2 (ja) 2017-09-06
US9427427B2 (en) 2016-08-30
PL2948141T3 (pl) 2025-09-15
EP2948141C0 (en) 2025-05-14
IL239657A0 (en) 2015-08-31
BR112015015758B1 (pt) 2022-01-04
AU2014210103A1 (en) 2015-06-11
PH12015501620B1 (en) 2018-08-24
EA201591276A1 (ru) 2016-01-29
JP2016505029A (ja) 2016-02-18
ZA201504187B (en) 2018-11-28
PH12015501620A1 (en) 2015-09-28
IL239657B (en) 2019-05-30
CA2892025A1 (en) 2014-07-31
BR112015015758B8 (pt) 2021-10-13
NZ708272A (en) 2020-07-31
US20170000764A1 (en) 2017-01-05
MY192032A (en) 2022-07-24
CR20150287A (es) 2015-09-01
US10034854B2 (en) 2018-07-31

Similar Documents

Publication Publication Date Title
PE20151335A1 (es) Composicion farmaceutica con biodisponibilidad mejorada
AR098576A1 (es) Producto farmacéutico
EA201500653A1 (ru) Композиции, содержащие триазольное соединение
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
PH12020550703A1 (en) Sulfonamide compounds and use thereof
EA201790389A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
EA201591632A1 (ru) Цитотоксические и антимитотические соединения и способы их применения
EA201590953A1 (ru) Пирролидиновые модуляторы gpr40
EA033811B1 (ru) Стабильные бесконсервантные мидриатические и противовоспалительные растворы для инъекций
EA201390198A1 (ru) Гетероциклическое соединение
MX2015011913A (es) Moduladores de acido oxabiciclo[2.2.2] gpr120.
MX2015010106A (es) Moduladores de la proteina activadora de 5-lipoxigenasa.
CL2018000158A1 (es) Composiciones y métodos para inhibir la expresión del gen alas1 (divisional de solicitud 20160772)
EA201691881A1 (ru) Новые соединения
EA201591618A1 (ru) Замещенные имидазопиридазины
EA201391481A1 (ru) Аналоги эпоксиэйкозатриеновой кислоты и способы их получения и использования
EA201591712A1 (ru) Антибиотические композиции на основе цефтолозана
EA201790570A1 (ru) Модуляторы р2х7
EA201891804A1 (ru) Тетрациклиновые соединения
CO2018007663A2 (es) Compuestos indolinonas y su uso en el tratamiento de enfermedades fibróticas
CA2891755C (en) Substituted pyrido-piperazinone derivatives as gamma secretase modulators
EA201690972A1 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
MX2013006418A (es) Derivados de oxazolil-metileter como agonistas del receptor de alx.
PH12018500378B1 (en) Novel annelated phenoxyacetamides
PH12014502465A1 (en) Fluorinated bridged spiro[2.4]heptane derivatives as alx receptor agonists